Zdrowie i gospodarka · 11/06/2012

FDA Announces Draft Guidance for Industry: Revised Labeling Recommendations for Plasma-Derived Products to Reduce vCJD Risk

The Food and Drug Administration (FDA) has released a draft document proposing amendments to labeling recommendations for plasma-derived products, including albumin, to reduce the risk of transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by blood and blood products, with the goal of finalizing revised labeling recommendations by an unspecified date.